In clinical trial, scientists hope to train immune system to attack cancer

June 10, 2013 by Krista Conger

(Medical Xpress)—Training our immune systems to fight cancer is an appealing prospect. Why wouldn't we want to launch our own internal army against one of our most-hated foes? But the process is a bit like learning to spot a single traitor in a stadium full of innocent bystanders. After all, at the most basic level, cancer cells are simply our own tissue making bad choices about how to grow and spread.

And there's the rub: The immune system's ability to protect against foreign invaders like bacteria or viruses hinges on its ability to differentiate them from our body's own tissues, to which it must not react (a phenomena called ). So it's a catch-22 when researchers attempt to prime B and T cells, macrophages and all of our many other to wipe out cancer cells. Often, what seems to be a promising response is dulled over time as immune cells called T , or Tregs, recognize the cancerous tissue as "self" and call off the attack.

Now, Ronald Levy, MD, professor of oncology at the School of Medicine and pioneer in the field of , and postdoctoral scholar Aurelien Marabelle, MD, have shown it's possible to perpetuate an anti-cancer immune response in by blocking the activity of Tregs with specific antibodies injected directly into the tumor site. The work, which has resulted in the recent initiation of a phase-1 and -2 clinical trial in humans, was published May 24 in the Journal of Clinical Investigation.

"These monoclonal antibodies target and eliminate T regulatory cells mixed in with the tumor that dampen the immune response against it," Levy said. "With these negative regulatory cells out of the way, the killer of the immune system are unleashed to seek and destroy the cancer cells wherever they are in the body, including in the brain."

Levy and his colleagues studied laboratory mice in which human had been implanted under the skin or injected into the blood. Once tumors were established, they treated the mice with a combination of two highly specific, or monoclonal, antibodies that recognize and bind to two molecules on the surface of the Treg cells.

Although some of these anti-Treg antibodies have already been approved for use in humans (one, ipilimumab, marketed as Yervoy, is currently used to treat metastatic melanoma), they can have negative side effects. That's because they're injected in fairly large doses into a patient's blood stream, inhibiting the Tregs not just in the tumor, but throughout the body. As a result, even normal, healthy tissues is subject to attack from the immune system.

Levy and his colleagues found that injecting much smaller amounts of the anti-Treg antibodies directly into the animals' tumors effectively targeted the Treg cells. What's more, coupling this treatment with the local injection of a molecule known to rev up the anti-tumor immune response causes an effect that ripples throughout the body to other organs and the central nervous system.

"We have found in animal experiments that by injecting certain into cancer in one place in the body we can trigger the immune system to fight cancer throughout the body," Levy said. "This result has the potential to change the way we use the immune system to treat cancer."

The researchers saw that the triple treatment—the two anti-Treg antibodies plus an injection of a molecule to stimulate the anti-cancer immune response—in one tumor site was highly effective even in mice with distant metastases. The animals lived longer and were resistant to a second administration of the .

The ability of the treatment to induce a response in distant tumor sites is particularly interesting, say the researchers, because some sites in the central nervous system are very difficult to target or reach with conventional therapies. Holbrook Kohrt, MD, PhD, assistant professor of oncology, will now be leading a parallel phase-1 and -2 clinical trial in patients with melanoma, lymphoma and colon cancers.

Explore further: Modulating the immune system to combat metastatic cancer

Related Stories

Modulating the immune system to combat metastatic cancer

May 24, 2013
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Promising drug prevents cancer cells from shutting down immune system

June 4, 2013
(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...

Study reveals that chemotherapy works in an unexpected way

April 4, 2013
It's generally thought that anticancer chemotherapies work like antibiotics do, by directly killing off what's harmful. But new research published online on April 4 in the Cell Press journal Immunity shows that effective ...

Anti-CD47 antibody may offer new route to successful cancer vaccination

May 21, 2013
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...

Targeted stimulation of immune pathway may help body fight back against liver cancer

June 5, 2013
Though it originates from the body's own cells, a tumor is as much of a hostile invader as any virus or bacterium. If the immune system is sufficiently sensitized, it can mount a counterattack just as it might fight an infection. ...

'Two-faced' cells discovered in colon cancer: Immune cells can suppress or promote tumor growth

December 13, 2012
Northwestern Medicine researchers have discovered a "two-faced" group of cells at work in human colon cancer, with opposing functions that can suppress or promote tumor growth. These cells are a subset of T-regulatory (Treg) ...

Recommended for you

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Skewing the aim of targeted cancer therapies

August 15, 2017
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.